Snke and Precision NeuroMed Partner to Accelerate Learning Cycles in Precision Brain Therapies Snke, a pioneering health tech company, and Precision NeuroMed (PNM), a clinical-stage biotechnology company advancing precision therapeutics for central nervous system (CNS) diseases, announced a partnership to streamline and…
Mevion Announces First Clinical Treatment on the MEVION S250-FIT™ Proton Therapy System Mevion Medical Systems, a global leader in compact proton therapy, announced that the world’s first clinical proton therapy treatment delivered inside an existing conventional radiation therapy vault has…
Single Blood Test Simultaneously Captures Immune, Stromal, and Tumor Signals Linked to Immunotherapy Response and Resistance in Sarcoma Aqtual, Inc., a precision medicine company developing active chromatin cell-free DNA (cfDNA) diagnostics for oncology and chronic disease, announced new findings demonstrating…
Aphios Corporation Announces Notice of Allowance for Novel Bryoid Composition Patent Targeting Alzheimer’s Disease, Multiple Sclerosis, HIV Latency and Cancer Aphios Corporation announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a…
Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies Biomunex Pharmaceuticals, a biopharmaceutical company specialized in the discovery and development of innovative immunotherapies based on bispecific and multi-specific…
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis Baszucki Group announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic…
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present multiple abstracts at the 2026 American Society of…
Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence Cellares, the first Integrated Development and Manufacturing Organization and ProTgen, a biotechnology company pioneering targeted Notch activators to reactivate the…
VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, announced MuteFree™ AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in gene therapy…
Genialis Supermodel Predicts Patient Response to HER2-Targeted Therapy Enhertu Genialis, the therapeutic intelligence company, announced it will present the first results from a new AI-based algorithm designed to distinguish between patients more likely to benefit from treatment with trastuzumab deruxtecan (Enhertu®, T-DXd).…
Quiver Bioscience Receives Strategic Investment From the Porta Family to Advance UBE3A ASO Therapeutic Program for Dup15q Syndrome Quiver Bioscience a discovery technology and therapeutics company advancing programs for the treatment of serious central nervous system (CNS) disorders, today announced…
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma CatalYm announced that the first patient has been dosed in the GDFATHER-HCC-01 trial The trial evaluates the company’s lead anti-GDF-15…